A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Monday, October 26, 2015
MS World Presents: Multiple Sclerosis NEWS FROM THE CONFERENCE CENTER
MSWORLD EXPRESS NEWS
NEWS FROM THE CONFERENCE CENTER
October 7th - 10th Barcelona, Spain
This week in our newsletter, we are featuring two videos from Day 1 of ECTRIMS (European Committee
for Treatment and Research in Multiple Sclerosis).
The Focus on
Progressive Multiple Sclerosis
Dr. Daniel Kantor talks with Dr. Theodore
Brown, Director of Rehabilitation at the Evergreen Health MS Center about
the opening lecture on Progressive forms of Multiple Sclerosis. Click here to watch now.
Volume in Multiple Sclerosis
Dr. Daniel Kantor
talks to Dr Mark Freeman, Professor of Neurology at the University of
Ottawa, Canada about measuring brain volume while taking Aubagio. Click here to watch now.
What to Expect When Starting Lemtrada
Dr. Kantor talks with Dr. Chris Laganke from Coleman,
Alabama about the procedure and what to expect when starting Lemtrada. Click here to watch now.
Favorable Outcomes for PPMS and RRMS
Dr. Kantor talks
with Dr. Barry Hendin, Clinical Professor at the University of Arizona
about Ocrelizumab and it’s favorable outcomes for both relapsing remitting
MS and primary progressive MS.